A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission with GSK1605786A in Subjects with Moderately-to-Severely Active Crohn�s Disease

To induce clinical response (CDAI decrease from baseline ? 100 points) and/or remission (CDAI <150) following 12 weeks of treatment with one of two active doses of gsk1605786a for qualification of subjects for enrolment into a follow-on 52-week maintenance study (ccx114157).>